According to our latest research, the global Migraine Drugs market size reached USD 6.9 billion in 2024, reflecting a robust expansion fueled by rising migraine prevalence and advancements in therapeutic options. The market is projected to grow at a CAGR of 8.3% from 2025 to 2033, reaching an estimated USD 13.2 billion by 2033. This growth trajectory is primarily driven by the increasing burden of migraine worldwide, heightened awareness about novel treatment modalities, and the introduction of innovative drug classes such as CGRP antagonists. As per the latest research, the market landscape is evolving rapidly, with pharmaceutical companies investing heavily in research and development to address unmet clinical needs and improve patient outcomes.https://growthmarketreports.com/report/migraine-drugs-market-global-industry-analysis